Escitalopram vs venlafaxine XR treatment of major depressive disorder

被引：0
|
作者：
Montgomery, SA [1 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Dept Psychiat, London, England
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2004年 / 14卷
关键词：
D O I：
10.1016/S0924-977X(04)80166-4
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S207 / S207
页数：1
相关论文
共 50 条
  • [41] Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder
    Bose, Anjana
    Korotzer, Andrew
    Gommoll, Carl
    Li, Dayong
    DEPRESSION AND ANXIETY, 2008, 25 (10) : 854 - 861
  • [42] Patterns of cardiorespiratory coordination in young women with recurrent major depressive disorder treated with escitalopram or venlafaxine
    Chang, Jae Seung
    Ha, Kyooseob
    Yoon, In-Young
    Yoo, Cheol Sung
    Yi, Sang Hoon
    Her, Ju Young
    Ha, Tae Hyon
    Park, Taesung
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2012, 39 (01): : 136 - 142
  • [43] Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. (vol 31, pg 122, 2006)
    Kennedy, SH
    Andersen, HF
    Lam, RW
    JOURNAL OF PSYCHIATRY & NEUROSCIENCE, 2006, 31 (04): : 228 - 228
  • [44] Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder
    Nierenberg, Andrew A.
    Trivedi, Madhukar H.
    Gaynes, Bradley N.
    Mitchell, Jeff
    Davis, Lori L.
    Husain, Mustafa M.
    Wisniewski, Stephen R.
    Fava, Maurizio
    Warden, Diane
    Luther, James F.
    van Nieuwenhuizen, Adrienne O.
    Morris, David W.
    Shelton, Richard C.
    Rush, A. John
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2009, 43 (10): : 956 - 967
  • [45] Escitalopram in the treatment of major depressive disorder in adolescent patientsProfile report
    Lily P. H. Yang
    Lesley J. Scott
    CNS Drugs, 2010, 24 : 621 - 623
  • [46] Venlafaxine XR Does Not Alter Biomarkers of Bone Turnover in Older Adults With Major Depressive Disorder
    Shea, Marcie L.
    Garfield, Lauren D.
    Mulsant, Benoit H.
    Reynolds, Charles
    Civitelli, Roberto
    Teitelbaum, Steven
    Lenze, Eric J.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2012, 20 (03): : S97 - S97
  • [47] APPLICATION OF ANALYTICAL HIERARCHY PROCESS FOR COMPARING VORTIOXETINE TO AGOMELATINE AND VENLAFAXINE XR IN MAJOR DEPRESSIVE DISORDER
    Briquet, B.
    Diamand, F.
    Francois, C.
    Brignone, M.
    VALUE IN HEALTH, 2017, 20 (05) : A292 - A292
  • [48] COST-UTILITY ANALYSIS EVALUATING VORTIOXETINE VERSUS VENLAFAXINE XR AND AGOMELATINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN TAIWAN
    Brignone, M.
    Atsou, K.
    Reynaud-Mougin, C.
    Chen, W.
    Milea, D.
    VALUE IN HEALTH, 2016, 19 (07) : A841 - A842
  • [49] Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder
    Soares, Claudio N.
    Thase, Michael E.
    Clayton, Anita
    Guico-Pabia, Christine J.
    Focht, Kristen
    Jiang, Qin
    Kornstein, Susan G.
    Ninan, Phil
    Kane, Cecelia P.
    Cohen, Lee S.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (04): : 700 - 711
  • [50] A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium
    Demyttenaere, K
    Hemels, MEA
    Hudry, J
    Annemans, L
    CLINICAL THERAPEUTICS, 2005, 27 (01) : 111 - 124
12345